Cardiff Oncology, Inc. (NASDAQ:CRDF) to Post Q1 2025 Earnings of ($0.28) Per Share, William Blair Forecasts

Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) - Research analysts at William Blair issued their Q1 2025 earnings per share estimates for shares of Cardiff Oncology in a research note issued on Tuesday, April 9th. William Blair analyst A. Hsieh forecasts that the company will post earnings of ($0.28) per share for the quarter. The consensus estimate for Cardiff Oncology's current full-year earnings is ($0.98) per share. William Blair also issued estimates for Cardiff Oncology's Q2 2025 earnings at ($0.27) EPS, Q3 2025 earnings at ($0.31) EPS and Q4 2025 earnings at ($0.31) EPS.

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) last announced its earnings results on Thursday, February 29th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.26) by $0.05. Cardiff Oncology had a negative return on equity of 50.13% and a negative net margin of 8,492.01%. The company had revenue of $0.16 million for the quarter, compared to analyst estimates of $0.08 million.

Several other equities research analysts have also issued reports on the company. HC Wainwright upped their price target on Cardiff Oncology from $12.00 to $14.00 and gave the company a "buy" rating in a research report on Wednesday, March 6th. Piper Sandler upped their price target on Cardiff Oncology from $5.00 to $7.00 and gave the company an "overweight" rating in a research report on Friday, March 1st.

Cardiff Oncology Price Performance

Shares of CRDF stock traded down $0.06 on Friday, hitting $5.61. 824,997 shares of the stock traded hands, compared to its average volume of 1,565,476. The company has a market capitalization of $250.65 million, a PE ratio of -6.03 and a beta of 1.94. Cardiff Oncology has a 1-year low of $0.94 and a 1-year high of $6.42. The company's fifty day moving average is $3.79 and its 200 day moving average is $2.18.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its stake in Cardiff Oncology by 10.6% during the 3rd quarter. Vanguard Group Inc. now owns 1,942,048 shares of the company's stock worth $2,990,000 after buying an additional 186,392 shares during the last quarter. BlackRock Inc. grew its stake in shares of Cardiff Oncology by 1.1% in the first quarter. BlackRock Inc. now owns 757,818 shares of the company's stock worth $1,250,000 after purchasing an additional 7,972 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of Cardiff Oncology by 48.1% in the second quarter. Renaissance Technologies LLC now owns 727,616 shares of the company's stock worth $1,601,000 after purchasing an additional 236,158 shares in the last quarter. State Street Corp grew its stake in shares of Cardiff Oncology by 1.6% in the first quarter. State Street Corp now owns 704,237 shares of the company's stock worth $1,747,000 after purchasing an additional 10,792 shares in the last quarter. Finally, Citigroup Inc. grew its stake in shares of Cardiff Oncology by 651,061.0% in the first quarter. Citigroup Inc. now owns 651,161 shares of the company's stock worth $1,074,000 after purchasing an additional 651,061 shares in the last quarter. 16.29% of the stock is currently owned by institutional investors.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.